ataluren

Also known as PTC124, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid, EC-000.2051

Ataluren, sold under the brand name Translarna, is a medication for the treatment of Duchenne muscular dystrophy. It was designed by PTC Therapeutics.

Key facts

Drug.Verifiedfields: changed
Drug.Watchedfields: changed
Drug.image: Ataluren.svg
Drug.image_class: skin-invert-image
Drug.image2: Ataluren ball-and-stick model.png
Drug.image_class2: bg-transparent
Drug.tradename: Translarna
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: M09
Drug.ATC_suffix: AX03
Drug.legal_UK: POM
Drug.legal_EU: Rx-only
Drug.CAS_number: 775304-57-9
Drug.PubChem: 11219835
Drug.IUPHAR_ligand: 7341
Drug.DrugBank: DB05016
Drug.ChemSpiderID: 9394889
Drug.UNII: K16AME9I3V

via Wikipedia infobox

Wikidata facts

Mass: 284.05972

Show 4 more facts

chemical formula: C₁₅H₉FN₂O₃
World Health Organisation international non-proprietary name: 阿他卢仑
canonical SMILES: C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F
Commons category: Ataluren

Sources (5)

via Wikidata · CC0

~6 min read

Article

10 sections

Contents

Medical use
Contraindications
Adverse effects
Interactions
Pharmacology
Chemistry
History
Society and culture
Legal status
References

Ataluren, sold under the brand name Translarna, is a medication for the treatment of Duchenne muscular dystrophy. It was designed by PTC Therapeutics.

==Medical use== Ataluren is used in the European Union to treat people with Duchenne muscular dystrophy who have a nonsense mutation in the dystrophin gene, can walk, and are more than five years old.